Sprint Bioscience

Sprint Bioscience is a Swedish biopharmaceutical company focused on discovering and developing preclinical cancer drug programs. The company builds its portfolio in Stockholm and Huddinge, where it advances internally generated oncology programs that are intended to be partnered out to international pharmaceutical companies.

— Sprint Bioscience
%
Preclinical oncology programs55% Internally generated cancer drug programs advanced through discovery and preclinical development.
Strategic partnering and licensing35% Licensing and collaboration agreements that monetize programs through partners.
Research and milestone income10% Research funding, milestone payments, and other partner-related program income.

Sprint Bioscience sells primarily to international pharmaceutical and biotech companies that license preclinical...

  • International pharmaceutical companiesprimary

    License preclinical cancer programs and pay for access to differentiated assets.

  • Biotechnology partnersprimary

    Enter collaborations or option deals around specific discovery programs.

  • Research and development collaboratorssecondary

    Provide research funding or milestone support tied to program progress.

Sprint Bioscience is headquartered in Stockholm and operates from Huddinge, near Karolinska University Hospital and...

  • •Headquartered in Stockholm, Sweden
  • •Operations based in Huddinge near Karolinska institutions
  • •Commercial partners are international rather than purely domestic
  • •Revenue exposure follows licensing counterparties and collaboration geography
  • •Swedish cost base with global partner-facing business model

The company’s strategy is to identify promising oncology biology, build preclinical programs, and partner each program...

01
Advance preclinical oncology assets to partnering stageshort-term

Partnering is the core monetization model for each program.

02
Broaden the program portfolio across key biology areasmedium-term

A diversified pipeline increases the chance of repeat deal flow.

03
Maintain financial strength for development continuitymedium-term

Discovery-stage biotech needs funding to sustain long development cycles.

Sprint Bioscience faces the typical risks of preclinical biotech: scientific failure, long development timelines, and...

high

Development failure in preclinical programs

Discovery-stage assets can fail on biology, safety, or commercial fit before monetization.

Scope
Pipeline programs
Materiality
high
high

Partner and counterparty dependence

The business model relies on strategic partners to generate licensing and milestone income.

Scope
Licensing agreements and collaborations
Materiality
high
high

Liquidity and financing needs

Research and drug development require ongoing funding before product revenue exists.

Scope
Operating cash flow and capital markets access
Materiality
high
medium

Foreign exchange risk

Reportedly, revenues are mainly in USD while a large share of costs is in SEK.

Scope
Transaction exposure
Materiality
medium
medium

Regulatory and industry change

Oncology drug development is affected by evolving scientific, legal, and regulatory standards.

Scope
Drug development and partnering environment
Materiality
medium
Revenue recognition for licensing and milestones
Affects quarterly comparability and reported sales timing
Impairment and valuation of development assets
Can materially affect operating result
IFRS 16
Lease accounting under RFR 2 / IFRS 16 disclosure
Affects balance sheet presentation and leverage perception
Foreign currency effects
Can move operating result without underlying business change

BeyondSpring Inc.

BYSI · Pharmaceutical Preparations

SPRUCE BIOSCIENCES, INC.

SPRB · Pharmaceutical Preparations

RHYTHM PHARMACEUTICALS, INC.

RYTM · Pharmaceutical Preparations

SUTRO BIOPHARMA, INC.

STRO · Biological Products, (No Diagnostic Substances)

CG Oncology, Inc.

CGON · Biological Products, (No Diagnostic Substances)

Passage BIO, Inc.

PASG · Biological Products, (No Diagnostic Substances)

: 11/08/2026